他拉唑帕利联合恩扎卢胺治疗转移性去势抵抗性前列腺癌:随机安慰剂对照III期TALAPRO-2研究的安全性分析
基于TALAPRO-2随机III期研究,分析他拉唑帕利联合恩扎卢胺在转移性去势抵抗性前列腺癌中的安全性。全人群(n=398)和HRR缺陷人群(n=198)中,3/4级TEAE发生率分别为71.9%和66.2%,最常见血液学毒性为贫血(46.7%和40.9%)、中性粒细胞减少(18.3%和18.7%)和血小板减少(7.3%和7.1%)。结论认为该方案安全性总体可控。
要点
- 全人群3/4级TEAE发生率为71.9%,HRR缺陷人群为66.2%。
- 3/4级贫血发生率全人群46.7%、HRR缺陷人群40.9%。
- 他拉唑帕利停药率全人群18.8%、HRR缺陷人群10.1%。
核心结论
- 在转移性去势抵抗性前列腺癌的全人群和HRR缺陷人群中,他拉唑帕利联合恩扎卢胺的安全性总体可控。
研究设计与样本
- 随机、安慰剂对照、III期TALAPRO-2研究的安全性分析,他拉唑帕利联合恩扎卢胺安全性人群包括队列1全人群398例和合并HRR缺陷人群198例。
- 患者接受他拉唑帕利0.5 mg(中度肾功能损害者0.35 mg)和恩扎卢胺160 mg每日一次。
- 安全性分析评估常见治疗中出现的不良事件(TEAE)及其类型、严重程度、发生时间、严重性和与研究治疗的关系。
主要发现
- 全人群(n=398)和HRR缺陷人群(n=198)中,他拉唑帕利联合恩扎卢胺的全因3/4级TEAE发生率分别为71.9%和66.2%。
- 最常见的3/4级血液学TEAE为贫血(全人群46.7% vs HRR缺陷人群40.9%)、中性粒细胞减少(18.3% vs 18.7%)和血小板减少(7.3% vs 7.1%)。
- 3/4级贫血的中位发生时间在全人群和HRR缺陷人群均为3.3个月,3/4级中性粒细胞减少均为2.3个月,3/4级血小板减少分别为2.3个月和1.5个月。
- 血红蛋白最大下降分别发生在治疗13周和15周后。
- 他拉唑帕利停药率在全人群为18.8%,在HRR缺陷人群为10.1%;TEAE通过剂量中断(62.1%和57.6%)、剂量降低(52.8%和52.0%)、血液学支持治疗(13.1%和10.6%)和输注浓缩红细胞(39.2%和35.9%)进行管理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in patients with metastatic castration-resistant prostate cancer (mCRPC). In both the all-comers and homologous recombination repair (HRR)-deficient populations, talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide. METHODS: The talazoparib plus enzalutamide safety populations in TALAPRO-2 included 398 patients from cohort 1 (all-comers, unselected for HRR gene alterations) and 198 patients from the combined HRR-deficient population (patients from the all-comers population with HRR gene alterations plus subsequently enrolled patients with HRR gene alterations; cohort 2). Patients received talazoparib 0.5 mg (0.35 mg, moderate renal impairment) and enzalutamide 160 mg once daily. Safety analyses evaluated common treatment-emergent adverse events (TEAE), their type, severity, timing, seriousness, and relationship to study treatment. RESULTS: In the all-comers (n = 398) and HRR-deficient populations (n = 198), all-cause grade 3/4 (G3/4) TEAEs with talazoparib plus enzalutamide were reported in 71.9 % and 66.2 % of patients, respectively. Most common G3/4 hematologic TEAEs were anemia (46.7 % and 40.9 %, respectively), neutropenia (18.3 % and 18.7 %), and thrombocytopenia (7.3 % and 7.1 %). Median time to event was 3.3 and 3.3 months for G3/4 anemia, 2.3 and 2.3 months for G3/4 neutropenia, and 2.3 and 1.5 months for G3/4 thrombocytopenia. Maximum hemoglobin reduction occurred after 13 and 15 weeks of treatment. 18.8 % and 10.1 % of patients discontinued talazoparib. TEAEs were managed with dose interruption (62.1 % and 57.6 %), reduction (52.8 % and 52.0 %), hematologic supportive care (13.1 % and 10.6 %), and packed red blood cell transfusions (39.2 % and 35.9 %). CONCLUSION: Talazoparib plus enzalutamide had a generally manageable safety profile in patients with mCRPC within the all-comers and the HRR-deficient populations. GOV IDENTIFIER: NCT03395197.
引用
- Azad AA, Fizazi K, Matsubara N, et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024. PMID: 39486165. doi:10.1016/j.ejca.2024.115078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。